Indaptus TherapeuticsINDP
Market Cap: $15.3M
About: Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Employees: 7
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
24% more funds holding
Funds holding: 17 [Q1] → 21 (+4) [Q2]
0.13% more ownership
Funds ownership: 6.89% [Q1] → 7.02% (+0.13%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4% less capital invested
Capital invested by funds: $1.32M [Q1] → $1.26M (-$53.8K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for INDP.